SLC25A25-AS1: A Potential Drug Target and Biomarker (G100289019)

Target Name: SLC25A25-AS1

NCBI ID: G100289019

SLC25A25-AS1

Other Name(s): SLC25A25 antisense RNA 1 | HRCEG

SLC25A25-AS1: A Potential Drug Target and Biomarker

Sodium-glucose cotransporter 25 (SLC25A25) is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the transport of both sodium and glucose across the end membrane of epithelial cells. It has been identified as a potential drug target due to its critical role in the regulation of body temperature, and its expression has been shown to be affected in various diseases, including cancer. In this article, we will discuss SLC25A25-AS1, its potential as a drug target and biomarker, and its current research in the field.

SLC25A25 is a member of the SLC family of transmembrane proteins, which are involved in the regulation of solute transport across the end membrane of epithelial cells. The SLC25A25 gene was identified and its gene product was shown to be expressed in various tissues and cells, including the heart, the kidney, the liver, and the brain. SLC25A25 is responsible for the transport of both sodium and glucose across the end membrane of epithelial cells, which is the main barrier that separates the inside of the cell from the outside. This is important for maintaining the proper levels of these two essential nutrients in the body, as well as regulating the body's temperature.

SLC25A25 has been shown to play a critical role in the regulation of body temperature by controlling the movement of water molecules into and out of the cells. It has been shown to be involved in the regulation of vasodilation, which is important for maintaining blood flow and temperature regulation. In addition, SLC25A25 has also been shown to be involved in the regulation of the production of heat, which is important for maintaining the body's temperature during physical activity.

SLC25A25 has also been identified as a potential drug target due to its involvement in various diseases, including cancer. Studies have shown that SLC25A25 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting SLC25A25 may be a promising strategy for the development of new cancer therapies.

In addition to its potential as a drug target, SLC25A25 has also been shown to be a potential biomarker for certain diseases. For example, studies have shown that SLC25A25 is downregulated in various types of cancer, including breast, ovarian, and prostate cancer, and that this downregulation is associated with poor prognosis. Therefore, measuring SLC25A25 levels in cancer samples may be a useful biomarker for the diagnosis and prognosis of these diseases.

SLC25A25 has also been shown to be involved in the regulation of various cellular processes in the body, including cell signaling, DNA replication, and cell death. This suggests that SLC25A25 may be a useful target for the development of new therapies that target these processes.

In conclusion, SLC25A25 is a protein that is expressed in the endoplasmic reticulum and is involved in the transport of both sodium and glucose across the end membrane of epithelial cells. Its expression has been shown to be affected in various diseases, including cancer, and it has been identified as a potential drug target. In addition, SLC25A25 has also been shown to be involved in the regulation of body temperature and various cellular processes, making it a potential biomarker for certain diseases. Further research is needed to fully understand the role of SLC25A25 in the regulation of body temperature and other cellular processes, as well as its potential as a drug target and biomarker.

Protein Name: SLC25A25 Antisense RNA 1

The "SLC25A25-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A25-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets